KRAS mutations are notoriously difficult to target with traditional therapies for several reasons. Firstly, the KRAS protein has a high affinity for GTP, making it hard to disrupt its activity. Secondly, its smooth, shallow surface lacks suitable binding pockets for small molecules. Lastly, KRAS mutations are common, making it a crucial target for developing effective cancer treatments.
